Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sarepta Therapeutics
Thumbnail
July 06, 2022

ICNMD 2022 – still unclear whether Sarepta can accelerate

New data with SRP-9001 look decent, but filing plans remain uncertain.

Thumbnail
June 24, 2022

Sarepta loses its Momentum

A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.

Article image
Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.

Article image
Vantage logo
May 11, 2022

Opportunities arise for once-spurned partners

Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?

Article image
Vantage logo
April 14, 2022

Is biopharma getting better at accelerated approval conversions?

Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.

Article image
Vantage logo
March 15, 2022

Bridgebio looks to lead limb girdle pipeline

Article image
Vantage logo
January 11, 2022

JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry

But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.

Article image
Vantage logo
September 29, 2021

Pfizer adds to gene therapy woes

But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.

Article image
Vantage logo
September 01, 2021

Astellas’s gene therapy aspirations crumble

AT132 has prompted more safety concerns, this time at a lower dose than before.

Article image
Vantage logo
July 09, 2021

Alzheimer’s and Covid-19 developers make hay on the stock markets

Big risers include Eli Lilly, Biogen, Moderna and Biontech.

Article image
Vantage logo
July 07, 2021

US regulator throws Chemocentryx a debatable lifeline

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.